Objective To visually analyze the relevant research on immune regulation of Tripterygium wilfordii Hook.f. aiming to explore the current research status, hotspots, and trends in this field.

Methods Relevant literature published on CNKI and Web of Science from January 2006 to December 2025 was retrieved and screened based on inclusion and exclusion criteria, and CiteSpace software was used to analyze publication volume, author and institutional collaborations, and keywords.

Results A total of 962 Chinese and English literature was included, and the annual publication volume reached its peak in 2019 and then stabilized. There were 183 core authors for Chinese literature and 119 core authors for English literature. There were 55 core publishing institutions for Chinese literature and 40 core publishing institutions for English literature. The research hotspots on immune regulation of Tripterygium wilfordii Hook.f. mainly focused on its immune regulation mechanism, the therapeutic effect and its preparations on immune related diseases, pharmacological effects, research on combination therapy, and regulation of inflammatory microenvironment.

Conclusion Research on the immune regulation of Tripterygium wilfordii Hook.f. mainly focuses on mechanisms, therapeutic effects, pharmacology, combination therapy, and inflammation regulation. However, high-quality clinical evidence is still insufficient, and in the future, it is necessary to deepen mechanism research, conduct standardized clinical trials, and promote its safe and precise application.

1. 陈文娟, 吴晶金. 雷公藤毒性及中药配伍减毒研究进展[J]. 中成药, 2023, 45(2): 499-503.ChenWJ, WuJJ. Research progress on toxicity of Tripterygium Wilfordii and detoxification by compatibility of Traditional Chinese Medicines[J]. Chinese Traditional Patent Medicine, 2023, 45(2): 499-503. DOI: 10.3969/j.issn.1001-1528.2023.02.027.

2. 刘为萍, 刘素香, 唐慧珠, 等. 雷公藤研究新进展[J]. 中草药, 2010, 41(7): 1215-1218. [LiuWP, LiuSX, TangHZ, et al. New research progress of Tripterygium Wilfordii[J]. Chinese Traditional and Herbal Drugs, 2010, 41(7): 1215-1218.ZCYO201007054.htm.https://www.cnki.com.cn/Article/CJFDTotal-

3. 马伟光, 张滔, 张超, 等. 有毒药物雷公藤的研究及展望[J]. 中华中医药杂志, 2006, 21(2): 117-120.MaWG, ZhangT, ZhangC, et al. Research and prospect on poisonous herb Tripterygium Wilfordii[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2006, 21(2): 117-120. DOI: 10.3969/j.issn.1673-1727.2006.02.017.

4. 薛璟, 贾晓斌, 谭晓斌, 等. 雷公藤化学成分及其毒性研究进展[J]. 中华中医药杂志, 2010, 25(5): 726-733. [XueJ, JiaXB, TanXB, et al. Research advances on chemical constituents and toxicity of Tripterygium Wilfordii Hook.f.[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2010, 25(5): 726-733]. https://xueshu.baidu.com/ndscholar/browse/detail?paperid=bf6907a7fa467a0d0f357df831a707ac

5. 苏桂花, 苑述刚, 马少丹, 等. 雷公藤的本草学及临床应用研究[J]. 河南中医, 2011, 31(4): 412-414.SuGH, YuanSG, MaSD, et al. Study on materia medica and clinical application of Tripterygium Wilfordii[J]. Henan Traditional Chinese Medicine, 2011, 31(4): 412-414. DOI: 10.16367/j.issn.1003-5028.2011.04.068.

6. 周嘉陵, 朱琦, 杨晓凌, 等. 雷公藤制剂副作用的临床观察[J]. 中国中西医结合杂志, 1999, 19(2): 14-16.ZhouJL, ZhuQ, YangXL, et al. Clinical observation of side effects of Tripterygium preparation[J]. Chinese Journal of Integrated Traditional and Western Medicine, 1999, 19(2): 14-16. DOI: 10.3321/j.issn:1003-5370.1999.02.005.

7. 封帆, 曾真, 叶新, 等. 510张门诊含雷公藤饮片中药处方的用药情况分析[J]. 中国医院用药评价与分析, 2021, 21(11): 1392-1394, 1398.FengF, ZengZ, YeX, et al. Application of traditional Chinese medicine containing Tripterygii Radix in 510 outpatient prescriptions[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2021, 21(11): 1392-1394, 1398. DOI: 10.14009/j.issn.1672-2124.2021.11.025.

8. 张威风, 李颖, 林梦璐, 等. 老年患者含雷公藤饮片中药处方用药规律分析[J]. 中南药学, 2023, 21(1): 229-234.ZhangWF, LiY, LinML, et al. Summary of traditional Chinese medicine prescriptions containing Tripterygium Wilfordii decoction pieces in elderly patients[J]. Central South Pharmacy, 2023, 21(1): 229-234. DOI: 10.7539/j.issn.1672-2981.2023.01.036.

9. GaoJ, ZhangY, LiuX, et al. Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives[J]. Theranostics, 2021, 11(15): 7199-7221. DOI: 10.7150/thno.57745.

10. 宋晓笛, 高畅. 雷公藤的药理作用、毒性及减毒策略研究进展[J]. 赣南医学院学报, 2023, 43(10): 987-992, 1004.SongXD, GaoC. Progress on pharmacology, toxicity and attenuated strategies of Tripterygium Wilfordii[J]. Journal of Gannan Medical University, 2023, 43(10): 987-992, 1004. DOI: 10.3969/j.issn.1001-5779.2023.10.001.

11. JiangM, XieY, WangP, et al. Research progress of Triptolide against fibrosis[J]. Drug Des Devel Ther, 2024, 18: 3255-3266. DOI: 10.2147/DDDT.S467929.

12. 姚骥如, 孙莹, 罗顺葵, 等. 雷公藤多苷的临床应用进展[J]. 中国新药与临床杂志, 2010, 29(3): 179-182. [YaoJR, SunY, LuoSK, et al. Progress of Tripterygium glycosides in clinical application[J]. Chinese Journal of New Drugs and Clinical Remedies, 2010, 29(3): 179-182.9749c7de469e2b5f00c2655.https://www.nstl.gov.cn/paper_detail.html?id=8dca769aa

13. 沈逸, 何东仪. 雷公藤免疫调节机制的研究进展[J]. 上海中医药杂志, 2012, 46(5): 97-101.ShenY, HeDY. Progress on immuno-regulatory mechanism of Tripterygium wilfordii[J]. Shanghai Journal of Traditional Chinese Medicine, 2012, 46(5): 97-101. DOI: 10.16305/j.1007-1334.2012.05.028.

14. 农程, 王欣之, 江振洲, 等. 雷公藤对免疫系统作用及机制研究进展[J]. 中国中药杂志, 2019, 44(16): 3374-3383.NongC, WangXZ, JiangZZ, et al. Progress of effect and mechanisms of Tripterygium wilfordii on immune system[J]. China Journal of Chinese Materia Medica, 2019, 44(16): 3374-3383. DOI: 10.19540/j.cnki.cjcmm.20190419.401.

15. 赵蓉英, 许丽敏. 文献计量学发展演进与研究前沿的知识图谱探析[J]. 中国图书馆学报, 2010, 36(5): 60-68.ZhaoRY, XuLM. The knowledge map of the evolution and research frontiers of the bibliometrics[J]. Journal of Library Science in China, 2010, 36(5): 60-68. DOI: 10.13530/j.cnki.jlis.2010.05.006.

16. 侯剑华, 胡志刚. CiteSpace软件应用研究的回顾与展望[J]. 现代情报, 2013, 33(4): 99-103.HouJH, HuZG. Review on the application of CiteSpace at home and abroad[J]. Journal of Modern Information, 2013, 33(4): 99-103. DOI: 10.3969/j.issn.1008-0821.2013.04.022.

17. 陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253.ChenY, ChenCM, LiuZY, et al. The methodology function of CiteSpace mapping knowledge domains[J]. Studies in Science of Science, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.

18. 朱素梅, 覃仕娜, 覃淼, 等. 基于CiteSpace的2016—2021年国内外中药质量标志物研究文献的计量学分析[J]. 中草药, 2021, 52(9): 2575-2588.ZhuSM, QinSN, QinM, et al. Bibliometric analysis of literatures on quality marker of Chinese medicine at domestic and abroad from 2016 to 2021 based on CiteSpace[J]. Chinese Traditional and Herbal Drugs, 2021, 52(9): 2575-2588. DOI: 10.7501/j.issn.0253-2670.2021.09.009.

19. 魏昕玥, 李思雅, 花海兵, 等. 五加属植物研究的知识图谱、全球专利及趋势前瞻探析[J]. 中草药, 2026, 57(7): 2655-2673.WeiXY, LiSY, HuaHB, et al. Analysis of knowledge graph, global patents and trend prospect of Eleutherococcus plants[J]. Chinese Traditional and Herbal Drugs, 2026, 57(7): 2655-2673. DOI: 10.7501/j.issn.0253-2670.2026.07.019.

20. 宗淑萍. 基于普赖斯定律和综合指数法的核心著者测评——以《中国科技期刊研究》为例[J]. 中国科技期刊研究, 2016, 27(12): 1310-1314.ZongSP. Evaluation of core authors based on price law and the comprehensive index method:a case study of Chinese Journal of Scientific and Technical Periodicals[J]. Chinese Journal of Scientific and Technical Periodicals, 2016, 27(12): 1310-1314.  DOI: 10.11946/cjstp. 201610080819.

21. 商素菲, 王进. 基于文献计量学和全球专利的半夏研究现状与发展趋势的可视化分析[J]. 中草药, 2025, 56(14): 5151-5168.ShangSF, WangJ. Visual analysis of research status and development trend of Pinelliae Rhizomabased on bibliometrics and global patents[J]. Chinese Traditional and Herbal Drugs, 2025, 56(14): 5151-5168. DOI: 10.7501/j.issn.0253-2670.2025.14.019.

22. WangZ, SunY, ShenR, et al. Global scientific trends on the immunomodulation of mesenchymal stem cells in the 21st century: a bibliometric and visualized analysis[J]. Front Immunol, 2022, 13: 984984. DOI: 10.3389/fimmu.2022.984984.

23. ZhaoJ, DiT, WangY, et al. Multi-glycoside of Tripterygium wilfordii Hook.f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses[J]. Int J Mol Med, 2016, 38(3): 747-757. DOI: 10.3892/ijmm.2016.2670.

24. LiuL, ChenX, LuY, et al. Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis in mice by targeting Langerhans cells[J]. Biomed Pharmacother, 2022, 147: 112644. DOI: 10.1016/j.biopha.2022.112644.

25. 龚雪, 汪元. 类风湿关节炎中医病因病机研究进展[J]. 风湿病与关节炎, 2020, 9(6): 62-65.GongX, WangY. Research progress of etiology and pathogenesis of rheumatoid arthritis in TCM[J].Rheumatism and Arthritis, 2020, 9(6): 62-65. DOI: 10.3969/j.issn.2095-4174.2020.06.019.

26. 姜泉, 王海隆, 巩勋, 等. 类风湿关节炎病证结合诊疗指南[J]. 中医杂志, 2018, 59(20): 1794-1800.JiangQ, WangHL, GongX, et al. Guidelines of diagnosis and treatment of rheumatoid arthritis disease and syndrome combination[J]. Journal of Traditional Chinese Medicine, 2018, 59(20): 1794-1800. DOI: 10.13288/j.11-2166/r.2018.20.018.

27. 杨丽, 刘荣华, 黄四碧, 等. 类风湿性关节炎的发病机制及治疗药物研究进展[J]. 中国药房, 2021, 32(17): 2154-2159.YangL, LiuRH, HuangSB, et al. Advances in pathogenesis and drug therapy for Rheumatoid Arthritis[J]. China Pharmacy, 2021, 32(17): 2154-2159. DOI: 10.6039/j.issn.1001-0408.2021.17.18.

28. LinN, ZhangYQ, JiangQ, et al. Clinical practice guideline for Tripterygium Glycosides/Tripterygium Wilfordii tablets in the treatment of rheumatoid arthritis[J]. Front Pharmacol, 2021, 11: 608703. DOI: 10.3389/fphar.2020.608703.

29. 贺超, 朱静茹, 戴森华. 雷公藤多苷治疗类风湿性关节炎(风寒湿痹阻证)临床研究[J]. 中华中医药学刊, 2024, 42(11): 81-84.HeC, ZhuJR, DaiSH. Clinical Study of Tripterygium Wilfordii polyglycoside in treatment of rheumatoid arthritis(wind-cold-dampness obstruction syndrome)[J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(11): 81-84. DOI: 10.13193/j.issn.1673-7717.2024.11.017.

30. ZhangX, XiaJ, JiangY, et al. 2023 International consensus guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis[J]. J Autoimmun, 2024, 142: 103148. DOI: 10.1016/j.jaut.2023.103148.

31. GengQ, LiuB, MaY, et al. Effects and safety of the Tripterygium glycoside adjuvant methotrexate therapy in rheumatoid arthritis: a systematic review and Meta-analysis[J]. Evid Based Complement Alternat Med, 2022, 2022: 1251478. DOI: 10.1155/2022/1251478.